Biotech Values

[DewDiligence]

MNTA – I’ve confirmed two points regarding the Lovenox ANDA from HSP:

• HSP is seeking to market a generic version of Lovenox vials, but not a generic version of Lovenox syringes.

• Vials comprise only 1% of dollar sales in the US Lovenox market.

No one I have spoken to knows why HSP is not pursuing a generic version of the syringe. (HSP itself won’t comment.) However, that fact that they’re not pursuing it means that HSP’s ANDA can be ignored as round-off error in any economic analysis of the US Lovenox market.